Patient-Reported Outcomes by Baseline Body Surface Area Involvement Among Individuals Initiating Biologic Therapy: Results from the CorEvitas Psoriasis Registry
Abstract Introduction Psoriasis body surface area (BSA) of 10% or more has been a major criterion for determining systemic therapy eligibility. However, patients with BSA < 10% and even ≤ 3% may have high disease burden and difficulties accessing biologics. To assess psoriasis burden among patien...
Saved in:
| Main Authors: | April W. Armstrong, Steven R. Feldman, Timothy Fitzgerald, Theodore Alkousakis, Adam Sima, Alvin Li, Hyung-Joo Kang, Sandra I. Main, Saakshi Khattri, Linda Stein Gold |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2025-06-01
|
| Series: | Dermatology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s13555-025-01456-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Disease burden and patient characteristics associated with systemic therapy utilization among adults with atopic dermatitis: data from CorEvitas Atopic Dermatitis Registry
by: Jonathan I. Silverberg, et al.
Published: (2024-12-01) -
EVITA: IMAGE BY HER DISCOURS
by: GALA Romanova
Published: (2016-06-01) -
Efficacy of modified enfortumab vedotin ineligible criteria (mEVITA) in advanced urothelial carcinoma
by: Takafumi Fukushima, et al.
Published: (2025-07-01) -
Real-World Skin Clearance and Quality of Life with risankizumab in Patients with Psoriasis with Moderate Skin Involvement and Those Eligible for Systemic Therapy Per International Psoriasis Council Classification
by: Bruce Strober, et al.
Published: (2025-07-01) -
CHRONIC COR PULMONALE
by: V. S. Zadionchenko, et al.
Published: (2003-08-01)